5002012025-07-012025-09-305002012025-09-305002012025-03-315002012025-04-012025-09-305002012025-07-012025-09-30in-capmkt:OtherExpenses1Member5002012025-07-012025-09-30in-capmkt:OtherExpenses2Member5002012025-07-012025-09-30in-capmkt:OtherExpenses3Member5002012025-04-012025-09-30in-capmkt:OtherExpenses1Member5002012025-04-012025-09-30in-capmkt:OtherExpenses2Member5002012025-04-012025-09-30in-capmkt:OtherExpenses3Member5002012025-07-012025-09-30in-capmkt:ReportableSegments1Member5002012025-07-012025-09-30in-capmkt:ReportableSegments2Member5002012025-07-012025-09-30in-capmkt:ReportableSegments3Member5002012025-07-012025-09-30in-capmkt:ReportableSegments4Member5002012025-04-012025-09-30in-capmkt:ReportableSegments1Member5002012025-04-012025-09-30in-capmkt:ReportableSegments2Member5002012025-04-012025-09-30in-capmkt:ReportableSegments3Member5002012025-04-012025-09-30in-capmkt:ReportableSegments4Member5002012025-07-012025-09-30in-capmkt:ReportableSegments1Member5002012025-07-012025-09-30in-capmkt:ReportableSegments2Member5002012025-07-012025-09-30in-capmkt:ReportableSegments3Member5002012025-07-012025-09-30in-capmkt:ReportableSegments4Member5002012025-04-012025-09-30in-capmkt:ReportableSegments1Member5002012025-04-012025-09-30in-capmkt:ReportableSegments2Member5002012025-04-012025-09-30in-capmkt:ReportableSegments3Member5002012025-04-012025-09-30in-capmkt:ReportableSegments4Member5002012025-07-012025-09-30in-capmkt:ReportableSegments1Member5002012025-09-30in-capmkt:ReportableSegments1Member5002012025-07-012025-09-30in-capmkt:ReportableSegments2Member5002012025-09-30in-capmkt:ReportableSegments2Member5002012025-07-012025-09-30in-capmkt:ReportableSegments3Member5002012025-09-30in-capmkt:ReportableSegments3Member5002012025-07-012025-09-30in-capmkt:ReportableSegments4Member5002012025-09-30in-capmkt:ReportableSegments4Member5002012025-07-012025-09-30in-capmkt:ReportableSegments1Member5002012025-09-30in-capmkt:ReportableSegments1Member5002012025-07-012025-09-30in-capmkt:ReportableSegments2Member5002012025-09-30in-capmkt:ReportableSegments2Member5002012025-07-012025-09-30in-capmkt:ReportableSegments3Member5002012025-09-30in-capmkt:ReportableSegments3Member5002012025-07-012025-09-30in-capmkt:ReportableSegments4Member5002012025-09-30in-capmkt:ReportableSegments4Member5002012025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15002012025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500201INDIAGLYCONOTLISTEDINE560A01023INDIA GLYCOLS LIMITEDMain BoardEquity2025-04-012026-03-312025-11-142025-11-07INRCroresQuarterlySecond quarterMulti segment2025-11-1416:00:002025-11-1417:30:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated2412400000021700000241457000006608500000632500000-3825000003211000004928000003848000001536800000023425200000720500000072050000097200000883000001855000000535000000000115600000650600000-1400000649200000650600000-1400000649200000309600000510.5110.510010.5110.51Note on Financial Results: <BR> At point no.26 'Face value of equity share capital' of Rs.5/- is the Face value per equity share. <BR> (The Board of Directors of the Company at their meeting held on 30th May ,2025 had considered and approved the Stock Split/ Sub-division of every one equity share having face value of Rs.10/ each, fully paid UP, Into Two equity shares, having face value of Rs. 5/ -Each, fully paid-up and the same has been approved by the shareholders of the Company through Postal Ballot on 22nd July 2025. Further the Company has fixed 12th August 2025 as the "Record Date" tor determining the entitlement of eligible Equity Shareholders for the purpose of sub-division/split of equity shares of the Company. Accordingly, the equity shares has been increased from 3,09,61,500 Equity shares to 6,19,23,000 Equity shares.) <BR> <BR> Note on Cash Flow Statement: <BR> (1) Since there is no option to fill ‘adjustment for (Profit)/Loss on Sale of Property, plant & equipment’ and ‘Provision No Longer Required Written Back’ in the utility, the same are shown in 'Other adjustment for non-cash items'. <BR> The actual figures (Rs. in crore) are as follows: <BR> (a) Adjustment for (Profit)/Loss on Sale of Property, plant & equipment: -0.75 <BR> (b) Provision No Longer Required Written Back: -0.02 <BR> (c) Goverment Grants: -0.06 <BR> <BR> Clarification on Cash flow statement: <BR> The amount written in ‘Adjustment for decrease (increase) in trade receivables, current’ includes trade and other receivables and represents both current as well non-current part. <BR> The amount written in ‘Adjustment for decrease (increase) in trade payables, current’ includes trade and other payables and represents both current as well non-current part. 2025-04-012025-09-30UnauditedConsolidated491552000003570000049190900000132995000001075900000-7422000006317000009396000007293000003181750000047751300000143960000001439600000172900000185400000358300000010813000000003018000001383100000-570000013774000001383100000-57000001377400000309600000522.3422.340022.3422.34Exice Duty13202000000Power and Fuel1154900000Other Expenses1011100000Exice Duty27828600000Power and Fuel2070200000Other Expenses191870000037507700000266940000017300000012400000411270000049000004934000004611000000448178000001083470000003081600000178700000806700000054400000046110000004630000012626000001675460000061572400000309600000236267000002393630000023936300000117395000009509000001269040000056600000460910000027800000173839000008036300000170000082317000008233400000279540000019065100000115210000035000000202522000003763610000061572400000Note1: Since there is no option to fill 'Right to use assets' in the utility, the same is clubbed with 'Property, Plant and Equipment'. <BR> <BR> The actual figures (Rs. in crore) are as follows: <BR> (a) Property, Plant and Equipment: 3674.88 <BR> (b) Right to use assets: 75.89 <BR> <BR> Note2: Since there is no option to fill 'Lease Liabilities' in the utility, the same is clubbed with 'Other financial liabilities'.Bio-based Specialities and Performance Chemicals2883300000Potable Spirits16578200000Ennature Biopharma434400000Bio-Fuel4228100000Bio-based Specialities and Performance Chemicals5883200000Potable Spirits34628800000Ennature Biopharma939400000Bio-Fuel77038000002412400000049155200000002412400000049155200000Bio-based Specialities and Performance Chemicals314100000Potable Spirits723900000Ennature Biopharma9800000Bio-Fuel293600000Bio-based Specialities and Performance Chemicals640100000Potable Spirits1447200000Ennature Biopharma21800000Bio-Fuel5203000001341400000262940000049280000093960000012500000-516000008361000001741400000Bio-based Specialities and Performance Chemicals33462100000Potable Spirits5798100000Ennature Biopharma4413800000Bio-Fuel1263630000056310300000526210000061572400000Bio-based Specialities and Performance Chemicals6882300000Potable Spirits2904300000Ennature Biopharma779000000Bio-Fuel824200000113898000002624630000037636100000Share of Profit and loss of JV is clubbed with Unallocated corporate expences.942300000874100000595800000000000-3437900000000729300000000008310000002860000000000-83000000-250200000118940000000012590000001063500000000000006300000017141000000000000000000000006070000000-1590400000000000003320100000162830000099000000230000095330000000637200000110300000011030000068400000178700000Items that will not be reclassified to Profit or Loss-4300000-4300000Items that will not be reclassified to Profit or Loss-8000000-8000000-1100000-2000000-1800000-300000-1400000-5700000